Approximately 41,000 people are diagnosed with colorectal cancer (CRC) in the UK each year, and over 90% of cases are treated successfully following early detection.
However, to refer selectively those patients with suspected CRC in a primary care setting is immensely challenging. The recent revision of the National Institute for Health and Care Excellence (NICE) NG12 ‘red flag’ criteria for the two-week wait aims to increase the CRC detection rate.
For the first time, NG12 includes the option to test for occult blood in faeces. While intendedfor specific patient cohorts, the guidelines stop short of suggesting appropriate technologies and how to establish this new service. Although perceived as cheap, guaiac products are approximatel 100 times less sensitive than the modern quantitative faecal immunochemical tests (FITs) now available.
OC-Sensor, manufactured by Eiken Chemical Company, and distributed in the UK by MastGroup, is a leading quantitative FIT platform and the only quantitative FIT assay that has US Food and Drug Administration approval. Now, OC-Sensor has been adopted for laboratory use and CRC screening programmes in over 42 countries. The OC-Sensor technology is simple to use and provides a range of benefits to enhance user experience and streamline sample processing.
So, are you FIT for the future? Adopt OC-Sensor, the clear path to an effective, efficient service.
